Hal Allergy

Hal Allergy

Netherlands - Leiden
Biotechnology

Focus: Allergy Treatments

Hal Allergy is a life sciences company focused on Allergy Treatments.

Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT02991885HAL-MPE1 Safety and Tolerability Study
Phase 1
Phase 1
Clinical Trials (1)
NCT02163018HAL-MPE1 First-in-human
Phase 1
Phase 1
Clinical Trials (1)
NCT03758456HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human
Phase 1
SUBLIVAC FIX Mite mixture
House Dust Mite Allergy
Phase 1/2
Clinical Trials (1)
NCT02345278SUBLIVAC FIX Mite Mixture Dose Tolerability Study
Phase 1/2
Phase 2
Clinical Trials (1)
NCT00932607SUBLIVAC® Birch PROBE Study
Phase 2
Phase 2
Clinical Trials (1)
NCT01438463PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
Phase 2
SUBLIVAC FIX Phleum Prat.
Allergic Rhinitis
Phase 2
Clinical Trials (1)
NCT02556801Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
Phase 2
SUBLIVAC FIX Birch
Allergic Rhinitis
Phase 2
Clinical Trials (1)
NCT01639768SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding
Phase 2
PURETHAL Mites 20,000 AUeq/ml
Allergic Rhinitis
Phase 2
Clinical Trials (1)
NCT00973453Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients
Phase 2
SUBLIVAC FIX phleum prat.
Allergic Rhinitis
Phase 2
Clinical Trials (1)
NCT01682070SUBLIVAC FIX Phleum Pratense DT/DRF
Phase 2
Clinical Trials (1)
NCT02231307SUBLIVAC FIX Birch Phase III Short-term Efficacy
Phase 3
PURETHAL Mites 50,000 AUeq/ml
House Dust Mite Allergy
Phase 3
Clinical Trials (1)
NCT06920771A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Phase 3
SUBLIVAC® Grasses/Placebo treatment
Rhinitis, Allergic, Seasonal
Phase 3
Clinical Trials (1)
NCT00422149Twin SUBLIVAC® Grasses Clinical Efficacy Study
Phase 3
PURETHAL Birch, 20.000 AUM/ml
Allergic Rhinitis
Phase 4
Clinical Trials (1)
NCT01918956PURETHAL Birch RUSH Study
Phase 4
PURETHAL Grasses, 20.000 AUM/ml
Allergic Rhinitis
Phase 4
Clinical Trials (1)
NCT01059266PURETHAL Grasses Rush Study
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2020
Portfolio: 15 clinical trials
Publications: 20 in PubMed